• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Glucagon-like peptide-1 receptor agonist prescribing patterns in adolescents with type 2 diabetes.

作者信息

Bensignor Megan O, Wolf Jack M, Rudser Kyle D, Kelly Aaron S, Arslanian Silva

机构信息

Center for Pediatric Obesity Medicine, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA.

Division of Biostatistics, University of Minnesota, Minneapolis, Minnesota, USA.

出版信息

Diabetes Obes Metab. 2022 Jul;24(7):1380-1384. doi: 10.1111/dom.14681. Epub 2022 May 1.

DOI:10.1111/dom.14681
PMID:35491535
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9177669/
Abstract
摘要

相似文献

1
Glucagon-like peptide-1 receptor agonist prescribing patterns in adolescents with type 2 diabetes.2型糖尿病青少年患者中胰高血糖素样肽-1受体激动剂的处方模式
Diabetes Obes Metab. 2022 Jul;24(7):1380-1384. doi: 10.1111/dom.14681. Epub 2022 May 1.
2
Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population.医疗保险人群中2型糖尿病患者对胰高血糖素样肽-1受体激动剂（GLP-1RA）治疗的依从性
Adv Ther. 2017 Mar;34(3):658-673. doi: 10.1007/s12325-016-0470-y. Epub 2017 Jan 11.
3
Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents.胰高血糖素样肽-1 类似物治疗 2 型糖尿病：现有及新兴药物。
Drugs. 2011 Sep 10;71(13):1675-88. doi: 10.2165/11592810-000000000-00000.
4
[Effects of GLP-1 receptor agonists on carbohydrate metabolism control].胰高血糖素样肽-1受体激动剂对碳水化合物代谢控制的影响
Med Clin (Barc). 2014;143 Suppl 2:18-22. doi: 10.1016/S0025-7753(14)70104-6.
5
Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.用注射药物满足2型糖尿病治疗中未满足的需求：胰高血糖素样肽-1受体激动剂
J Fam Pract. 2017 Oct;66(10 Suppl):S12-S16.
6
Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis.胰高血糖素样肽-1受体激动剂对2型糖尿病患者腰围的影响：一项系统评价和网状Meta分析
Endocrine. 2015 Apr;48(3):794-803. doi: 10.1007/s12020-014-0373-0. Epub 2014 Aug 13.
7
FDA approval of GLP-1 receptor agonist (liraglutide) for use in children.美国食品药品监督管理局批准胰高血糖素样肽-1受体激动剂（利拉鲁肽）用于儿童。
Lancet Child Adolesc Health. 2019 Sep;3(9):595-597. doi: 10.1016/S2352-4642(19)30236-6. Epub 2019 Jul 22.
8
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.胰高血糖素样肽-1 受体激动剂对体重减轻的影响：随机对照试验的系统评价和荟萃分析。
BMJ. 2012 Jan 10;344:d7771. doi: 10.1136/bmj.d7771.
9
Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation.利拉鲁肽与艾塞那肽每周一次：持续性、依从性及早期停药情况
Clin Ther. 2016 Jan 1;38(1):149-60. doi: 10.1016/j.clinthera.2015.11.017. Epub 2015 Dec 17.
10
Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?胰高血糖素样肽-1 受体激动剂在 2 型糖尿病治疗中的应用：它们都一样吗？
Diabetes Metab Res Rev. 2019 Jan;35(1):e3070. doi: 10.1002/dmrr.3070. Epub 2018 Oct 4.

引用本文的文献

1
Effects of GLP-1 Receptor Agonists on Paediatric Population in a Real World Setting.胰高血糖素样肽-1受体激动剂在真实世界环境中对儿科人群的影响。
Endocrinol Diabetes Metab. 2025 May;8(3):e70053. doi: 10.1002/edm2.70053.
2
Parent and Guardian Opinions on Obesity Medications Use in Adolescents with Obesity and Related Comorbidities.家长和监护人对肥胖青少年及其相关合并症使用肥胖症药物的看法。
Child Obes. 2025 Jun;21(4):365-371. doi: 10.1089/chi.2024.0351. Epub 2024 Dec 18.
3
A clinician's guide to effects of obesity on childhood asthma and into adulthood.临床医生指南：肥胖对儿童哮喘及成年期的影响。
Expert Rev Respir Med. 2024 Oct;18(10):759-775. doi: 10.1080/17476348.2024.2403500. Epub 2024 Sep 16.
4
Euglycemic Diabetic Keto Acidosis in a Type 1 Diabetic Patient After Glucose Like Peptide-1 Administration: A Case Presentation.1 型糖尿病患者给予胰高血糖素样肽-1 后出现血糖正常的糖尿病酮症酸中毒：病例报告。
J Investig Med High Impact Case Rep. 2023 Jan-Dec;11:23247096231206333. doi: 10.1177/23247096231206333.
5
G Protein-Coupled Receptors and the Rise of Type 2 Diabetes in Children.G蛋白偶联受体与儿童2型糖尿病的增加
Biomedicines. 2023 May 29;11(6):1576. doi: 10.3390/biomedicines11061576.
6
Metabolic Contributions to Pathobiology of Asthma.代谢对哮喘病理生物学的影响。
Metabolites. 2023 Jan 31;13(2):212. doi: 10.3390/metabo13020212.
7
Mechanistic Links Between Obesity and Airway Pathobiology Inform Therapies for Obesity-Related Asthma.肥胖与气道病理生理学之间的机制联系为肥胖相关哮喘的治疗提供了信息。
Paediatr Drugs. 2023 May;25(3):283-299. doi: 10.1007/s40272-022-00554-7. Epub 2023 Jan 19.

本文引用的文献

1
14. Children and Adolescents: Standards of Medical Care in Diabetes-2022.14. 儿童和青少年：2022 年糖尿病医学护理标准。
Diabetes Care. 2022 Jan 1;45(Suppl 1):S208-S231. doi: 10.2337/dc22-S014.
2
Recent developments in GLP-1RA therapy: A review of the latest evidence of efficacy and safety and differences within the class.胰高血糖素样肽-1受体激动剂疗法的最新进展：疗效与安全性的最新证据及该类别内差异的综述
Diabetes Obes Metab. 2021 Sep;23 Suppl 3:30-39. doi: 10.1111/dom.14487.
3
Long-Term Complications in Youth-Onset Type 2 Diabetes.青少年 2 型糖尿病的长期并发症。
N Engl J Med. 2021 Jul 29;385(5):416-426. doi: 10.1056/NEJMoa2100165.
4
Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD-11.度拉糖肽3.0毫克和4.5毫克对2型糖尿病患者体重的影响：AWARD - 11探索性分析
Diabetes Obes Metab. 2021 Oct;23(10):2242-2250. doi: 10.1111/dom.14465. Epub 2021 Jun 29.
5
Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD-11 trial.在年龄小于 65 岁和大于等于 65 岁的患者中，度拉鲁肽 3.0 和 4.5 mg 的疗效和安全性：AWARD-11 试验的事后分析。
Diabetes Obes Metab. 2021 Oct;23(10):2279-2288. doi: 10.1111/dom.14469. Epub 2021 Jul 8.
6
Use of once-weekly semaglutide in patients with type 2 diabetes in routine clinical practice: Results from the SURE Canada multicentre, prospective, observational study.在常规临床实践中使用每周一次司美格鲁肽治疗 2 型糖尿病患者：来自 SURE 加拿大多中心、前瞻性、观察性研究的结果。
Diabetes Obes Metab. 2021 Oct;23(10):2269-2278. doi: 10.1111/dom.14468. Epub 2021 Aug 15.
7
Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study.在常规临床实践中早期使用口服司美格鲁肽的探索：IGNITE 研究。
Diabetes Obes Metab. 2021 Sep;23(9):2177-2182. doi: 10.1111/dom.14453. Epub 2021 Jun 16.
8
Effect of liraglutide treatment on body mass index and weight parameters in children and adolescents with type 2 diabetes: Post hoc analysis of the ellipse trial.利拉鲁肽治疗对2型糖尿病儿童和青少年体重指数及体重参数的影响：ELLIPSE试验的事后分析
Pediatr Obes. 2021 Aug;16(8):e12778. doi: 10.1111/ijpo.12778. Epub 2021 Feb 25.
9
Liraglutide hospital discharge trial: A randomized controlled trial comparing the safety and efficacy of liraglutide versus insulin glargine for the management of patients with type 2 diabetes after hospital discharge.利拉鲁肽出院试验：一项比较利拉鲁肽与甘精胰岛素治疗 2 型糖尿病患者出院后安全性和有效性的随机对照试验。
Diabetes Obes Metab. 2021 Jun;23(6):1351-1360. doi: 10.1111/dom.14347. Epub 2021 Mar 31.
10
GLP-1 agonists for obesity and type 2 diabetes in children: Systematic review and meta-analysis.GLP-1 激动剂治疗儿童肥胖和 2 型糖尿病：系统评价和荟萃分析。
Obes Rev. 2021 Jun;22(6):e13177. doi: 10.1111/obr.13177. Epub 2020 Dec 22.